AbbVie Aktie News

Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie's immunosuppressant portfolio helps it to produce steady revenue and profits.

AbbVie has increased its dividend by 333% since 2013. Coca-Cola is a Dividend King that still has plenty of growth potential.

Dividend-paying stocks can be great for investors of any age. The income they deliver can be invested in more shares of stock.

AbbVie's core products have ample growth potential over the next five years. The company also won't face a significant patent cliff in the near future.

Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large institutions frequently use the options market to place high-conviction bets before major news becomes public.

Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compar...

Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to improve the survival rate in patients in a late-stage study.

These stocks trade at forward earnings multiples of less than 16, well below the S&P 500 average. What's more, their longer-term price-to-earnings-growth ratios are attractive at less than 1.